Hims & Hers founder and CEO Andrew Dudum said via X, “As of this morning, providers on our platform can now send prescriptions for Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy and access self-pay pricing for our customers because of an expansion in our platform’s functionality. In many ways, today reminds me of Netflix’s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix’s success depended on its ability to become the distribution channel for a single film. They were missing the forest for the trees: Netflix wasn’t just renting DVDs. It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most. By offering a full range of FDA-approved GLP-1s on our platform, we’re similarly giving our customers more choices through all the tools we have available – and we’ll continue to push here on behalf of everyone who depends on us for their care.” Shares of Hims & Hers are up almost 7% in pre-market trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in?
- Balanced Risk/Reward Amid Peptide-Driven Rally and Regulatory Uncertainty
- Hims & Hers price target raised to $30 from $25 at BofA
- Amazon (AMZN) Steps Up Weight Loss Push, Knocks HIMS Stock Off the Scale
- Mixed options sentiment in Hims and Hers Health with shares down 4.05%
